Skye Bioscience Nimacimab Study Fails Primary Endpoint

Skye Bioscience reports mixed results for its weight-loss drug nimacimab: it failed alone due to suboptimal dosing, but adding it to semaglutide (Wegovy/Ozempic) resulted in significant extra weight loss without increasing common stomach or mental side effects.